PracticeUpdate: Haematology & Oncology

AMERICAN SOCIETY OF CLINICAL ONCOLOGY 2016 ANNUAL MEETING 12

PBS Information: TAFINLAR (dabrafenib) . Authority Required (STREAMLINED). Treatment of BRAF V600 mutation positive unresectable Stage III or Stage IV (metastatic) melanoma. Refer to the PBS Schedule for full Authority information.

PBS Information: MEKINIST (trametinib) . Authority Required (STREAMLINED). Treatment of BRAF V600 mutation positive unresectable Stage III or Stage IV (metastatic) melanoma in combination with dabrafenib. Refer to the PBS Schedule for full Authority information.

Mekinist ® (trametinib dimethyl sulfoxide) in combination with Tafinlar ® (dabrafenib mesilate) Please review full Mekinist ® (trametinib dimethyl sulfoxide) and Tafinlar ® (dabrafenib mesilate) product information before prescribing. Approved product information is available on request or online at www.novartis.com.au/products/healthcare-professionals.shtml.

PRACTICEUPDATE HAEMATOLOGY & ONCOLOGY